Carolinas Healthcare System Northeas
- Type
- Teaching hospital
- Where
- Concord, NC
- Medicare CCN
- 340001
- Received
- $6,480,778 in 903 records, 2020 ($543,873 general, $5,936,905 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 83 | $543,873 |
| 2020 | Research payment | 820 | $5,936,905 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 820 | $5,936,905 |
| Gift | 25 | $190,458 |
| Grant | 4 | $187,470 |
| Space rental or facility fees (teaching hospital only) | 20 | $107,809 |
| Royalty or License | 5 | $47,844 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 28 | $8,790 |
| Education | 1 | $1,500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Gilead Sciences, Inc. | $177,970 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-31 | Stryker Corporation | $6,442 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Stryker Corporation | $772 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Stryker Corporation | $420 | Gift | In-kind items and services | STRYKER AIR PUMP Device, PATIENT HANDLING - PH | 2020 | |
| 2020-12-29 | Genentech, Inc. | $42,091 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PHASE IB COMBO FOR HER2 BC WITH HERCEPTIN KADCYLA PERJETA APDL1 | 2020 |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-23 | Gilead Sciences, Inc. | $21,600 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $3,748 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-12-23 | Deciphera Pharmaceuticals Inc. | $2,459 | Research payment | Cash or cash equivalent | A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | 2020 | |
| 2020-12-23 | Gilead Sciences, Inc. | $1,724 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $1,431 | Research payment | Cash or cash equivalent | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2020 | |
| 2020-12-23 | Gilead Sciences, Inc. | $793 | Research payment | Cash or cash equivalent | Harvoni Drug, HCV | A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for H | 2020 |
| 2020-12-22 | Daiichi Sankyo Inc. | $9,000 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176B-D-312 | 2020 |
| 2020-12-22 | Daiichi Sankyo Inc. | $1,985 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176B-D-312 | 2020 |
| 2020-12-22 | Daiichi Sankyo Inc. | $1,000 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176B-D-312 | 2020 |
| 2020-12-22 | Daiichi Sankyo Inc. | $500 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | DU176B-D-312 | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-21 | Janssen Scientific Affairs, LLC | $35,449 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | DARA-OUT-046a Utilization of Daratumumab Combination Regimens at Academic Institutions in Patients with Multiple Myeloma | 2020 |
| 2020-12-21 | Janssen Scientific Affairs, LLC | $9,000 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | DARA-OUT-046a Utilization of Daratumumab Combination Regimens at Academic Institutions in Patients with Multiple Myeloma | 2020 |
| 2020-12-21 | Edwards Lifesciences Corporation | $2,479 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-12-21 | Janssen Research & Development, LLC | $1,050 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-12-18 | Janssen Research & Development, LLC | $11,032 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-18 | Janssen Research & Development, LLC | $9,189 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2020 | |
| 2020-12-17 | Edwards Lifesciences Corporation | $23,771 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-12-17 | Inari Medical, Inc. | $3,000 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-12-17 | Alnylam Pharmaceuticals Inc. | $325 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of | 2020 |
| 2020-12-16 | Incyte Corporation | $10,018 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-16 | Deciphera Pharmaceuticals Inc. | $4,429 | Research payment | Cash or cash equivalent | A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | 2020 | |
| 2020-12-16 | Deciphera Pharmaceuticals Inc. | $3,227 | Research payment | Cash or cash equivalent | A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | 2020 | |
| 2020-12-16 | Deciphera Pharmaceuticals Inc. | $2,740 | Research payment | Cash or cash equivalent | A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | 2020 | |
| 2020-12-16 | Deciphera Pharmaceuticals Inc. | $1,585 | Research payment | Cash or cash equivalent | A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | 2020 | |
| 2020-12-16 | Incyte Corporation | $1,335 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-16 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-15 | Allergan, Inc. | $2,688 | Research payment | Cash or cash equivalent | Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steato | 2020 | |
| 2020-12-15 | E.R. Squibb & Sons, L.L.C. | $2,000 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIB Primary CNS and Testicular Lymphoma mono | 2020 |
| 2020-12-15 | Smith+Nephew, Inc. | $1,830 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MICRORAPTOR Knotless Hip Device, Sports Med Hip | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $1,975 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Del | 2020 | |
| 2020-12-14 | Dynavax Technologies Corporation | $1,530 | Research payment | Cash or cash equivalent | Intratumoral SD-101 Drug | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-12-10 | Abbott Laboratories | $9,000 | Research payment | Cash or cash equivalent | HeartMate 3 Left Ventricular Dev Device, Cardiac Arrhythmias and Heart Failure | Antiplatelet Removal and HemocompatIbility Events in the HeartMate 3 Pump | 2020 |
| 2020-12-09 | Abbott Laboratories | $24,889 | Research payment | Cash or cash equivalent | TriClip Transcatheter Tricuspid Valve Repair System Device, Cardiac Arrhythmias and Heart Failure | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2020 |
| 2020-12-09 | Pharmacyclics LLC, an AbbVie Company | $15,074 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1123-CA | 2020 |
| 2020-12-09 | BeiGene, Ltd. | $3,900 | Research payment | In-kind items and services | BRUKINSA Drug, ONCOLOGY | A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma | 2020 |
| 2020-12-08 | E.R. Squibb & Sons, L.L.C. | $15,850 | Research payment | Cash or cash equivalent | YERVOY Biological, Oncology | Phase IV PMR - Dose Comparison 3 mg vs 10 mg | 2020 |
| 2020-12-08 | Karyopharm Therapeutics Inc. | $3,191 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | XPORT-COV-1001 | 2020 |
| 2020-12-08 | BeiGene, Ltd. | $1,431 | Research payment | Cash or cash equivalent | BRUKINSA Drug, ONCOLOGY | A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma | 2020 |
| 2020-12-08 | Karyopharm Therapeutics Inc. | $203 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | XPORT-COV-1001 | 2020 |
| 2020-12-07 | Boston Scientific Corporation | $8,892 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-12-07 | UCB SA | $1,500 | Research payment | Cash or cash equivalent | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of padsevonil a | 2020 | |
| 2020-12-07 | Boston Scientific Corporation | $1,385 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2020 |
| 2020-12-05 | Incyte Corporation | $2,660 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-03 | Janssen Research & Development, LLC | $2,940 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-12-03 | Janssen Research & Development, LLC | $1,040 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk | 2020 | |
| 2020-12-03 | Abbott Laboratories | $175 | Research payment | Cash or cash equivalent | HeartMate 3 Device, Cardiac Arrhythmias and Heart Failure | MOMENTUM 3 CAP Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3 Continued Acc | 2020 |
| 2020-12-03 | Abbott Laboratories | $175 | Research payment | Cash or cash equivalent | HeartMate 3 Device, Cardiac Arrhythmias and Heart Failure | MOMENTUM 3 CAP Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3 Continued Acc | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $249,827 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Pilot Study of Paclitaxel plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer The PePPy study | 2020 |
| 2020-12-02 | Gilead Sciences, Inc. | $12,800 | Research payment | Cash or cash equivalent | A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Re | 2020 | |
| 2020-12-02 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-02 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-30 | Janssen Research & Development, LLC | $13,453 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-11-24 | Daiichi Sankyo Inc. | $104,737 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-11-24 | Pharmacyclics LLC, an AbbVie Company | $8,847 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1123-CA | 2020 |
| 2020-11-24 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-24 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-24 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-23 | Edwards Lifesciences Corporation | $880 | Research payment | Cash or cash equivalent | Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System Trial #2018-02 | 2020 | |
| 2020-11-19 | Olympus America Inc. | $21,772 | Gift | In-kind items and services | 2020 | ||
| 2020-11-19 | Novartis Pharmaceuticals Corporation | $10,345 | Research payment | Cash or cash equivalent | INC280 Drug | A PHASE II MULTICENTER RANDOMIZED TWO ARM STUDY OF THE COMBINATION OF CAPMATINIB INC280 AN ORAL MET INHIBITOR AND SPARTA | 2020 |
| 2020-11-19 | Pharmacyclics LLC, an AbbVie Company | $6,985 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-11-19 | Merck Sharp & Dohme LLC | $3,282 | Research payment | In-kind items and services | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $21,901 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2020 |
| 2020-11-18 | Genentech, Inc. | $21,629 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PHASE IB COMBO FOR HER2 BC WITH HERCEPTIN KADCYLA PERJETA APDL1 | 2020 |
| 2020-11-18 | Genentech, Inc. | $11,985 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PHASE IB COMBO FOR HER2 BC WITH HERCEPTIN KADCYLA PERJETA APDL1 | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $4,503 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $1,724 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-11-18 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-18 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-18 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-18 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-18 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-18 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-18 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-18 | Gilead Sciences, Inc. | $25 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-11-16 | Janssen Research & Development, LLC | $9,855 | Research payment | Cash or cash equivalent | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | 2020 | |
| 2020-11-16 | Boston Scientific Corporation | $211 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SFA DES PIVOTAL | 2020 |
| 2020-11-13 | ABBVIE INC. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Humira Drug, Immunology | 2020 | |
| 2020-11-11 | Abbott Laboratories | $7,852 | Research payment | Cash or cash equivalent | Tendyne Mitral Valve System Device, Cardiac Arrhythmias and Heart Failure | Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Sy | 2020 |
| 2020-11-11 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2020 | |
| 2020-11-10 | BeiGene, Ltd. | $1,431 | Research payment | Cash or cash equivalent | BRUKINSA Drug, ONCOLOGY | A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma | 2020 |
| 2020-11-10 | Advanced Respiratory, Inc | $500 | Space rental or facility fees (teaching hospital only) | In-kind items and services | The Monarch Airway Clearance System Device, Airway Clearance Device | 2020 | |
| 2020-11-09 | Dynavax Technologies Corporation | $127,787 | Research payment | Cash or cash equivalent | Intratumoral SD-101 Drug | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-11-09 | Dynavax Technologies Corporation | $6,667 | Research payment | Cash or cash equivalent | Intratumoral SD-101 Drug | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-11-09 | Dynavax Technologies Corporation | $4,155 | Research payment | Cash or cash equivalent | Intratumoral SD-101 Drug | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2020 |
| 2020-11-05 | JAZZ PHARMACEUTICALS INC. | $50,811 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2020 |
| 2020-11-03 | Pharmacyclics LLC, an AbbVie Company | $9,000 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1145-LT | 2020 |
| 2020-11-03 | Genentech, Inc. | $4,949 | Research payment | Cash or cash equivalent | ROZLYTREK Biological, BioOncology | STARTRK 2 RXDX 101 02 | 2020 |
| 2020-11-03 | Janssen Research & Development, LLC | $1,976 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Ad | 2020 | |
| 2020-11-03 | Pharmacyclics LLC, an AbbVie Company | $1,500 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1145-LT | 2020 |
| 2020-11-02 | Boston Scientific Corporation | $4,886 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-11-02 | Edwards Lifesciences Corporation | $2,850 | Research payment | Cash or cash equivalent | CLASP II TR Pivotal, Study No. 2019-07 | 2020 | |
| 2020-10-30 | Smith+Nephew, Inc. | $3,737 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | REGENETEN Shoulder Device, Sports Med Shoulder | 2020 | |
| 2020-10-30 | Smith+Nephew, Inc. | $3,180 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Latarjet System Device, Sports Med Shoulder | 2020 | |
| 2020-10-30 | Smith+Nephew, Inc. | $2,234 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MICRORAPTOR Knotless Shoulder Device, Sports Med Shoulder | 2020 | |
| 2020-10-29 | Inari Medical, Inc. | $11,085 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-10-29 | Abbott Laboratories | $147 | Research payment | Cash or cash equivalent | HeartMate 3 Device, Cardiac Arrhythmias and Heart Failure | MOMENTUM 3 CAP Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3 Continued Acc | 2020 |
| 2020-10-29 | Abbott Laboratories | $147 | Research payment | Cash or cash equivalent | HeartMate 3 Device, Cardiac Arrhythmias and Heart Failure | MOMENTUM 3 CAP Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3 Continued Acc | 2020 |
| 2020-10-28 | Merck Sharp & Dohme LLC | $96,600 | Research payment | Cash or cash equivalent | MK-7684 Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2020 |
| 2020-10-28 | KLS-Martin L.P. | $10,047 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-10-28 | Pharmacyclics LLC, an AbbVie Company | $7,133 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1142-CA | 2020 |
| 2020-10-28 | Abbott Laboratories | $697 | Research payment | Cash or cash equivalent | HeartMate 3 Device, Cardiac Arrhythmias and Heart Failure | MOMENTUM 3 CAP Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3 Continued Acc | 2020 |
| 2020-10-28 | Abbott Laboratories | $697 | Research payment | Cash or cash equivalent | HeartMate 3 Device, Cardiac Arrhythmias and Heart Failure | MOMENTUM 3 CAP Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3 Continued Acc | 2020 |
| 2020-10-27 | Exelixis Inc. | $12,780 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib XL184) in Subjects with Radioiodine Refr | 2020 |
| 2020-10-27 | Zimmer Biomet Holdings, Inc. | $10,664 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2020 | |
| 2020-10-27 | Zimmer Biomet Holdings, Inc. | $4,950 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2020 | |
| 2020-10-27 | Merck Sharp & Dohme LLC | $3,089 | Research payment | In-kind items and services | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin | 2020 |
| 2020-10-27 | Takeda Pharmaceuticals U.S.A., Inc. | $2,179 | Research payment | Cash or cash equivalent | A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32 | 2020 | |
| 2020-10-26 | Janssen Research & Development, LLC | $17,502 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-10-26 | Janssen Research & Development, LLC | $3,018 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-10-26 | Janssen Research & Development, LLC | $1,470 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-10-26 | Genentech, Inc. | $292 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | BF1RST | 2020 |
| 2020-10-23 | E.R. Squibb & Sons, L.L.C. | $10,000 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIIB Dose Comparison N3 I1 vs I3 N1 in melanoma | 2020 |
| 2020-10-23 | Alnylam Pharmaceuticals Inc. | $525 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of | 2020 |
| 2020-10-22 | Horizon Therapeutics plc | $13,815 | Research payment | Cash or cash equivalent | KRYSTEXXA Biological, KRYSTEXXA | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPO | 2020 |
| 2020-10-22 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $4,630 | Research payment | Cash or cash equivalent | SAFETY STUDY OF ORAL EDARAVONE ADMINISTERED IN SUBJECTS WITH ALS | 2020 | |
| 2020-10-22 | Janssen Research & Development, LLC | $3,950 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Del | 2020 | |
| 2020-10-22 | Edwards Lifesciences Corporation | $434 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-10-21 | Gilead Sciences, Inc. | $37,749 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | $2,792 | Research payment | Cash or cash equivalent | Harvoni Drug, HCV | A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for H | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | $508 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-10-20 | Exelixis Inc. | $12,329 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib XL184) in Subjects with Radioiodine Refr | 2020 |
| 2020-10-19 | Janssen Scientific Affairs, LLC | $325 | Research payment | Cash or cash equivalent | INVEGA SUSTENNA Drug, Neuroscience | Impact of paliperidone palmitate on clinical, economic, and psychosocial outcomes in patients with schizophrenia from a | 2020 |
| 2020-10-19 | Boston Scientific Corporation | $211 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SFA DES PIVOTAL | 2020 |
| 2020-10-16 | Merck Sharp & Dohme LLC | $12,000 | Research payment | Cash or cash equivalent | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin | 2020 |
| 2020-10-15 | Alnylam Pharmaceuticals Inc. | $9,000 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $7,660 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2020 | |
| 2020-10-15 | Alnylam Pharmaceuticals Inc. | $3,465 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of | 2020 |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $2,300 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2020 | |
| 2020-10-15 | Regeneron Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2020 | |
| 2020-10-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,718 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2020 |
| 2020-10-15 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2020 | |
| 2020-10-14 | SEAGEN INC. | $238,800 | Research payment | In-kind items and services | ADCETRIS Biological, Oncology | A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin | 2020 |
| 2020-10-14 | SEAGEN INC. | $6,112 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-10-14 | KLS-Martin L.P. | $4,367 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-10-13 | Exelixis Inc. | $2,126 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-10-12 | Janssen Research & Development, LLC | $2,940 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-10-12 | Genentech, Inc. | $1,018 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | AN OPEN LABEL MULTICENTER EXTENSION STUDY | 2020 |
| 2020-10-08 | Smith+Nephew, Inc. | $2,770 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BIOSURE REGENESORB Device, Sports Med Knee | 2020 | |
| 2020-10-05 | Boston Scientific Corporation | $6,714 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-10-01 | Edwards Lifesciences Corporation | $16,495 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2020 | |
| 2020-10-01 | Abbott Laboratories | $4,135 | Research payment | Cash or cash equivalent | SJM Masters HP 15mm Rotatable Mechanical Heart Valve Device, Vascular | HALO Clinical Study: A Single Arm, Prospective, Non-randomized, Multi Center Investigation of the SJM Masters HP 15mm Ro | 2020 |
| 2020-09-30 | Merck Sharp & Dohme LLC | $4,971 | Research payment | Cash or cash equivalent | MK-7684 Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2020 |
| 2020-09-28 | Janssen Research & Development, LLC | $4,825 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-09-28 | Genentech, Inc. | $438 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | BF1RST | 2020 |
| 2020-09-24 | Janssen Research & Development, LLC | $3,950 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Del | 2020 | |
| 2020-09-24 | Exelixis Inc. | $3,167 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $63,871 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2020 |
| 2020-09-23 | Pharmacyclics LLC, an AbbVie Company | $4,021 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1142-CA | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $3,260 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-09-22 | Takeda Pharmaceuticals U.S.A., Inc. | $9,000 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF TAK-079 IN PATIENTS WI | 2020 | |
| 2020-09-17 | Karyopharm Therapeutics Inc. | $18,397 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | XPORT-COV-1001 | 2020 |
| 2020-09-17 | Regeneron Pharmaceuticals, Inc. | $10,000 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) | 2020 |
| 2020-09-17 | Regeneron Pharmaceuticals, Inc. | $4,000 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) | 2020 |
| 2020-09-17 | Regeneron Pharmaceuticals, Inc. | $2,590 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) | 2020 |
| 2020-09-17 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF TAK-079 IN PATIENTS WI | 2020 | |
| 2020-09-17 | Regeneron Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) | 2020 |
| 2020-09-16 | Takeda Pharmaceuticals U.S.A., Inc. | $19,000 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR | 2020 | |
| 2020-09-16 | Takeda Pharmaceuticals U.S.A., Inc. | $7,275 | Research payment | Cash or cash equivalent | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2020 | |
| 2020-09-16 | BeiGene, Ltd. | $3,900 | Research payment | In-kind items and services | BRUKINSA Drug, ONCOLOGY | A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma | 2020 |
| 2020-09-16 | Takeda Pharmaceuticals U.S.A., Inc. | $1,800 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR | 2020 | |
| 2020-09-16 | Takeda Pharmaceuticals U.S.A., Inc. | $500 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR | 2020 | |
| 2020-09-16 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2020 | |
| 2020-09-15 | Exelixis Inc. | $2,018 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-09-14 | ENCORE MEDICAL, LP | $5,525 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-09-11 | Roche Products Limited | $34,155 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PPMS | 2020 |
| 2020-09-11 | Roche Products Limited | $2,505 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PPMS | 2020 |
| 2020-09-11 | Merck Sharp & Dohme LLC | $509 | Research payment | In-kind items and services | MK-7684 Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2020 |
| 2020-09-10 | Karyopharm Therapeutics Inc. | $30,264 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | XPORT-COV-1001 | 2020 |
| 2020-09-10 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | MK-7684 Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2020 |
| 2020-09-10 | BeiGene, Ltd. | $2,863 | Research payment | Cash or cash equivalent | BRUKINSA Drug, ONCOLOGY | A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma | 2020 |
| 2020-09-10 | Takeda Pharmaceuticals U.S.A., Inc. | $492 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2020 |
| 2020-09-10 | Merck Sharp & Dohme LLC | $201 | Research payment | In-kind items and services | MK-7684 Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2020 |
| 2020-09-10 | Takeda Pharmaceuticals U.S.A., Inc. | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2020 |
| 2020-09-10 | Takeda Pharmaceuticals U.S.A., Inc. | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2020 |
| 2020-09-10 | Takeda Pharmaceuticals U.S.A., Inc. | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2020 |
| 2020-09-09 | Abbott Laboratories | $320 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-09-08 | Travere Therapeutics, Inc. | $9,000 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-09-08 | Boston Scientific Corporation | $5,682 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-09-08 | Travere Therapeutics, Inc. | $1,500 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-09-08 | Travere Therapeutics, Inc. | $500 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-09-08 | Merck Sharp & Dohme LLC | $263 | Research payment | In-kind items and services | MK-7684 Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $134 | Research payment | In-kind items and services | MK-7684 Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2020 |
The latest 200 records of 903.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Concord, NC, county Cabarrus County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Concord, NC | County Cabarrus County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 108,719 | 236,133 | 10,730,404 |
| Population, 2020 census P1 | 105,240 | 225,804 | 10,439,388 |
| Median age B01002 | 36.5 | 37.7 | 39.1 |
| Under 18 B01001 | 26.8% | 25.2% | 21.8% |
| 65 and over B01001 | 12.0% | 13.6% | 17.2% |
| Households B11001 | 38,669 | 84,246 | 4,282,345 |
| Foreign born B05002 | 13.5% | 10.8% | 9.1% |
| Median household income B19013 | $86,921 | $89,005 | $72,388 |
| Median family income B19113 | $104,221 | $106,314 | $90,290 |
| Per capita income B19301 | $42,090 | $42,636 | $41,385 |
| Poverty rate B17001 | 9.6% | 9.3% | 13.0% |
| Unemployment rate B23025 | 5.5% | 4.6% | 4.7% |
| Civilian labor force B23025 | 58,255 | 125,285 | 5,336,863 |
| Mean commute (minutes) B08013 | 26.9 | 27.3 | 25.1 |
| Bachelor's degree or higher B15003 | 40.9% | 37.9% | 35.7% |
| Housing units B25001 | 43,142 | 93,691 | 4,895,668 |
| Owner-occupied B25003 | 65.2% | 71.2% | 66.6% |
| Renters B25003 | 34.8% | 28.8% | 33.4% |
| Median home value B25077 | $353,700 | $354,800 | $288,900 |
| Median gross rent B25064 | $1,451 | $1,414 | $1,228 |
| White, not Hispanic B03002 | 49.4% | 57.3% | 60.0% |
| Black B03002 | 22.3% | 18.7% | 20.0% |
| Hispanic or Latino B03002 | 15.8% | 12.7% | 11.3% |
| Asian B03002 | 7.7% | 6.2% | 3.3% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Concord, NC.
Comments